Pre-Open Stock Movers 12/10: (CNTX) (AI) (ORCL) Higher; (ANGN) (CCNC) (MRNA) Lower (more...)
Pre-Open Stock Movers
Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) 22.6% LOWER; announced results from the exploratory phase-II GUARD trial of Angions ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.
Context Therapeutics Inc. (Nasdaq: CNTX) 16.8% HIGHER; announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).
Code Chain New Continent Limited (NASDAQ: CCNC) 15% LOWER; announced that it intends to offer shares of common stock and warrants to purchase common stock in a proposed underwritten public offering. The Company intends to use the net proceeds to purchase cryptocurrency mining equipment and for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
American Outdoor Brands (NASDAQ: AOUT) 17.9% LOWER; reported Q2 EPS of $0.58, $0.18 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $70.8 million versus the consensus estimate of $82.55 million. American Outdoor Brands sees FY2022 EPS of $2.02-$2.21, versus the consensus of $2.27. American Outdoor Brands sees FY2022 revenue of $280-285 million, versus the consensus of $294.1 million.
C3.ai, Inc. (NYSE: AI) 12.3% HIGHER; has established a new five-year Production-Other Transaction Agreement with the U.S. Department of Defense (DoD).
Moderna, Inc., (Nasdaq: MRNA) 11.7% LOWER; announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults. The Company also announced that the Phase 2 study of mRNA-1010 is now fully enrolled and preparation for the Phase 3 study is underway. Moderna also provided an update on its seasonal flu vaccine program including the announcement of two beyond quadrivalent seasonal flu development candidates (mRNA-1011 and mRNA-1012).
Oracle (NYSE: ORCL) 9.7% HIGHER; reported Q2 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $10.4 billion versus the consensus estimate of $10.21 billion.
Chewy (NYSE: CHWY) 7% LOWER; reported Q3 EPS of ($0.08), $0.04 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.21 billion versus the consensus estimate of $2.21 billion. Chewy sees Q4 2021 revenue of $2.4-2.44 billion, versus the consensus of $2.43 billion.
Academy Sports and Outdoor (NASDAQ: ASO) 6.8% HIGHER; reported Q3 EPS of $1.75, $0.72 better than the analyst estimate of $1.03. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.48 billion. Academy Sports and Outdoor sees FY2021 EPS of $7.21-$7.31, versus the consensus of $6.48. Academy Sports and Outdoor sees FY2021 revenue of $6.675-6.74 billion, versus the consensus of $6.6 billion.
National Beverage Corp. (NASDAQ: FIZZ) 6.8% LOWER; Q2 earnings, revenue miss.
Broadcom (NASDAQ: AVGO) 6.7% HIGHER; reported Q4 EPS of $7.81, $0.40 better than the analyst estimate of $7.41. Revenue for the quarter came in at $7.6 billion, may not compare versus the consensus estimate of $7.36 billion. Broadcom sees Q1 2022 revenue of $7.6 billion, versus the consensus of $7.25 billion. First quarter Adjusted EBITDA guidance of approximately 61.5 percent of projected revenue.
Jabil (NYSE: JBL) 4.5% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $75.00 (from $63.00).
R.R. Donnelley (NYSE: RRD) 3.9% HIGHER; Chatham Asset Management Increases Offer to $10.85 Per Share in Cash
Peloton Interactive (NASDAQ: PTON) 3.3% LOWER; Credit Suisse downgraded from Outperform to Neutral with a price target of $50.00 (from $112.00).
Bottomline Technologies (NASDAQ: EPAY) 3% HIGHER; is exploring a sale, according to Bloomberg, citing people with knowledge of the matter.
Southwest (NYSE: LUV) 3% LOWER; Goldman Sachs downgraded from Neutral to Sell with a price target of $36.00 (from $59.00).
Crown Holdings, Inc. (NYSE: CCK) 2% HIGHER; announced today that its Board of Directors authorized the repurchase of an aggregate amount of up to $3.0 billion of Company stock through the end of 2024.
lululemon athletica (NASDAQ: LULU) 2% LOWER; reported Q3 EPS of $1.62, $0.21 better than the analyst estimate of $1.41. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.43 billion. lululemon athletica sees Q4 2021 EPS of $3.25-$3.32, versus the consensus of $3.30. lululemon athletica sees Q4 2021 revenue of $2.125-2.165 billion, versus the consensus of $2.17 billion.
BioCryst Pharma (NASDAQ: BCRX) 1.5% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $16.00.